CB Insights
Technology Market Intelligence
Technology Market Intelligence
Public list: Pharma Startups (6570) Cancer Therapeutics (1180)
Ganymed Pharmaceuticals is a biopharmaceutical company that researches, develops, and produces pharmaceutical products and therapeutic drugs for the treatment of solid cancers. It focuses on developing ideal monoclonal antibodies (IMABs) that include...Show all
Company (Acquired)
Phone: +49 (0) 6131 / 1440-100
An der Goldgrube 12
Mainz, D-55131
Germany
| Total Funding | Date of Last Funding | |
|---|---|---|
| GANYMED Pharmaceuticals | $268M | Oct 28, 2016 |
| OncoMed Pharmaceuticals | $376.2M | Apr 23, 2019 |
| U3 Pharma | $55.2M | Dec 1, 2015 |
| See all 18 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Name | Firm |
|---|---|
| Login to see details | Future Capital |
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis | Apr 13, 2016 | Feb 23, 2021 | Patent |
| Antibodies for treatment of cancer expressing claudin 6 | Jul 05, 2018 | Feb 16, 2021 | Patent |
| Cancer therapy using cldn6 target-directed antibodies in vivo | Jan 09, 2018 | Nov 24, 2020 | Patent |
| Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | May 07, 2018 | Oct 27, 2020 | Patent |
| Antibodies specific for claudin 6 (cldn6) | Jan 31, 2018 | Aug 18, 2020 | Patent |
